Literature DB >> 15699172

Decay-accelerating factor (CD55) is expressed by neurons in response to chronic but not acute autoimmune central nervous system inflammation associated with complement activation.

Johan van Beek1, Marjan van Meurs, Bert A 't Hart, Herbert P M Brok, Jim W Neal, Alexandra Chatagner, Claire L Harris, Nader Omidvar, B Paul Morgan, Jon D Laman, Philippe Gasque.   

Abstract

There is compelling evidence that a unique innate immune response in the CNS plays a critical role in host defense and clearance of toxic cell debris. Although complement has been implicated in neuronal impairment, axonal loss, and demyelination, some preliminary evidence suggests that the initial insult consequently activates surrounding cells to signal neuroprotective activities. Using two different models of experimental autoimmune encephalomyelitis, we herein demonstrate selective C1q complement activation on neuron cell bodies and axons. Interestingly, in brains with chronic but not acute experimental autoimmune encephalomyelitis, C3b opsonization of neuronal cell bodies and axons was consistently associated with robust neuronal expression of one of the most effective complement regulators, decay-accelerating factor (CD55). In contrast, levels of other complement inhibitors, complement receptor 1 (CD35), membrane cofactor protein (CD46), and CD59 were largely unaffected on neurons and reactive glial cells in both conditions. In vitro, we found that proinflammatory stimuli (cytokines and sublytic doses of complement) failed to up-regulate CD55 expression on cultured IMR32 neuronal cells. Interestingly, overexpression of GPI-anchored CD55 on IMR32 was capable of modulating raft-associated protein kinase activities without affecting MAPK activities and neuronal apoptosis. Critically, ectopic expression of decay-accelerating factor conferred strong protection of neurons against complement attack (opsonization and lysis). We conclude that increased CD55 expression by neurons may represent a key protective signaling mechanism mobilized by brain cells to withstand complement activation and to survive within an inflammatory site.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15699172     DOI: 10.4049/jimmunol.174.4.2353

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status.

Authors:  Maria I Leite; Margaret Jones; Philipp Ströbel; Alexander Marx; Ralf Gold; Erik Niks; Jan J G M Verschuuren; Sonia Berrih-Aknin; Francesco Scaravilli; Aurea Canelhas; B Paul Morgan; Angela Vincent; Nick Willcox
Journal:  Am J Pathol       Date:  2007-08-03       Impact factor: 4.307

2.  Role of decay-accelerating factor in regulating survival of human cervical cancer cells.

Authors:  Ling-Juan Gao; Lan Ding; Shu-Yu Guo; You-Qun Cai; Ya-Juan Su; Hui Gong; Yun Liu; Chen Chen; Ping-Qing Gu
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-10       Impact factor: 4.553

3.  Cooperation of decay-accelerating factor and membrane cofactor protein in regulating survival of human cervical cancer cells.

Authors:  Ling-Juan Gao; Shu-Yu Guo; You-Qun Cai; Ping-Qing Gu; Ya-Juan Su; Hui Gong; Yun Liu; Chen Chen
Journal:  BMC Cancer       Date:  2009-10-30       Impact factor: 4.430

4.  Membrane attack complex inhibitor CD59a protects against focal cerebral ischemia in mice.

Authors:  Denise Harhausen; Uldus Khojasteh; Philip F Stahel; B Paul Morgan; Wilfried Nietfeld; Ulrich Dirnagl; George Trendelenburg
Journal:  J Neuroinflammation       Date:  2010-03-04       Impact factor: 8.322

5.  The role of the complement system and the activation fragment C5a in the central nervous system.

Authors:  Trent M Woodruff; Rahasson R Ager; Andrea J Tenner; Peter G Noakes; Stephen M Taylor
Journal:  Neuromolecular Med       Date:  2009-09-11       Impact factor: 3.843

6.  A comparison of physiological and transcriptome responses to water deprivation and salt loading in the rat supraoptic nucleus.

Authors:  Michael P Greenwood; Andre S Mecawi; See Ziau Hoe; Mohd Rais Mustafa; Kory R Johnson; Ghada A Al-Mahmoud; Lucila L K Elias; Julian F R Paton; Jose Antunes-Rodrigues; Harold Gainer; David Murphy; Charles C T Hindmarch
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-01-28       Impact factor: 3.619

7.  The regulation of the CNS innate immune response is vital for the restoration of tissue homeostasis (repair) after acute brain injury: a brief review.

Authors:  M R Griffiths; P Gasque; J W Neal
Journal:  Int J Inflam       Date:  2010-08-09

8.  Complement activation in the Parkinson's disease substantia nigra: an immunocytochemical study.

Authors:  David A Loeffler; Dianne M Camp; Stephanie B Conant
Journal:  J Neuroinflammation       Date:  2006-10-19       Impact factor: 8.322

9.  Modulation of CD59 expression by restrictive silencer factor-derived peptides in cancer immunotherapy for neuroblastoma.

Authors:  Rossen M Donev; Lisa C Gray; Baalasubramanian Sivasankar; Timothy R Hughes; Carmen W van den Berg; B Paul Morgan
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

10.  Expression of glycosylphosphatidylinositol-anchored CD59 on target cells enhances human NK cell-mediated cytotoxicity.

Authors:  Nader Omidvar; Eddie C Y Wang; Paul Brennan; M Paula Longhi; Richard A G Smith; B Paul Morgan
Journal:  J Immunol       Date:  2006-03-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.